Clinical Trial Update: Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS [Phase 1]

View source ↗

Summary

Phase 1 study of AUTX-703 for relapsed or refractory acute myeloid leukemia and relapsed/refractory myelodysplastic syndromes is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• AUTX-703

Snippet

Sponsor: Auron Therapeutics, Inc. | Conditions: Relapsed Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML) | Phase 1 | Status: ACTIVE_NOT_RECRUITING